• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases.不可切除的原发性结直肠癌和同步转移患者化疗后的肠道并发症。
Gut. 2003 Apr;52(4):568-73. doi: 10.1136/gut.52.4.568.
2
Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.同步转移性结直肠癌原发肿瘤切除的预后价值:来自 ARCAD 数据库的一线随机试验的个体患者数据分析。
Eur J Cancer. 2018 Mar;91:99-106. doi: 10.1016/j.ejca.2017.12.014. Epub 2018 Jan 30.
3
Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer.不可切除的 IV 期结直肠癌无症状患者姑息治疗后的肠道并发症。
J Surg Oncol. 2010 Jul 1;102(1):94-9. doi: 10.1002/jso.21577.
4
Benefit of Surgical Resection of the Primary Tumor in Patients Undergoing Chemotherapy for Stage IV Colorectal Cancer with Unresected Metastasis.手术切除 IV 期结直肠癌伴未切除转移患者化疗中原发肿瘤的获益。
J Gastrointest Surg. 2018 Mar;22(3):460-466. doi: 10.1007/s11605-017-3617-5. Epub 2017 Nov 9.
5
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment.同步性IV期结直肠癌患者接受联合化疗而非手术作为初始治疗时原发性肿瘤的转归
J Clin Oncol. 2009 Jul 10;27(20):3379-84. doi: 10.1200/JCO.2008.20.9817. Epub 2009 Jun 1.
6
Surgery of the primary in stage IV colorectal cancer with unresectable metastases.无法切除转移灶的 IV 期结直肠癌的手术治疗。
Eur J Cancer. 2011 Sep;47 Suppl 3:S61-6. doi: 10.1016/S0959-8049(11)70148-4.
7
Is complete liver resection without resection of synchronous lung metastases justified?不切除同步性肺转移灶而进行完整的肝切除是否合理?
Ann Surg Oncol. 2015 May;22(5):1585-92. doi: 10.1245/s10434-014-4207-3. Epub 2014 Nov 6.
8
Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.结直肠癌合并同期不可切除转移患者行原发灶切除的临床意义。
J Surg Oncol. 2014 Aug;110(2):214-21. doi: 10.1002/jso.23607. Epub 2014 Mar 26.
9
The beneficial effect of palliative resection in metastatic colorectal cancer.姑息性切除术治疗转移性结直肠癌的疗效。
Br J Cancer. 2013 Apr 16;108(7):1425-31. doi: 10.1038/bjc.2013.94. Epub 2013 Mar 12.
10
Risk factors for the requirement of surgical or endoscopic interventions during chemotherapy in patients with uncomplicated colorectal cancer and unresectable synchronous metastases.单纯性结直肠癌和不可切除性同步转移患者化疗期间手术或内镜干预需求的危险因素。
J Surg Oncol. 2014 Dec;110(7):839-44. doi: 10.1002/jso.23725. Epub 2014 Jul 18.

引用本文的文献

1
Stage IV Rectal Cancer and Timing of Surgical Approach.IV期直肠癌与手术入路时机
Clin Colon Rectal Surg. 2023 Aug 10;37(4):248-255. doi: 10.1055/s-0043-1770719. eCollection 2024 Jul.
2
Crosstalk Between the Nervous System and Colorectal Cancer.神经系统与结直肠癌之间的相互作用
Neurosci Bull. 2025 Jan;41(1):93-106. doi: 10.1007/s12264-024-01238-7. Epub 2024 Jun 16.
3
Nonoperative management of the primary tumor in patients with unresectable stage IV colon cancer treated with systemic chemotherapy: Higher complication rates for left-sided colon tumors.不可切除的 IV 期结肠癌患者接受全身化疗后,对原发肿瘤采用非手术治疗:左侧结肠癌的并发症发生率更高。
Eur J Surg Oncol. 2024 Jan;50(1):107294. doi: 10.1016/j.ejso.2023.107294. Epub 2023 Nov 23.
4
Clinical Outcomes of Upfront Primary Tumor Resection in Synchronous Unresectable Metastatic Colorectal Cancer.同期不可切除转移性结直肠癌初始原发性肿瘤切除的临床结局
Cancers (Basel). 2023 Oct 19;15(20):5057. doi: 10.3390/cancers15205057.
5
Colorectal liver metastases: state-of-the-art management and surgical approaches.结直肠癌肝转移:最新治疗方法与手术入路。
Langenbecks Arch Surg. 2022 Aug;407(5):1765-1778. doi: 10.1007/s00423-022-02496-7. Epub 2022 Apr 9.
6
Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases.对于有无症状原发性病变和同步不可切除转移灶的结肠癌患者,先行诱导化疗再行原发性肿瘤切除并不能带来生存获益。
Front Oncol. 2022 Jan 31;12:747124. doi: 10.3389/fonc.2022.747124. eCollection 2022.
7
Serum oxidative stress is an independent prognostic marker in colorectal cancer.血清氧化应激是结直肠癌的一个独立预后标志物。
Transl Cancer Res. 2019 Sep;8(5):1699-1708. doi: 10.21037/tcr.2019.08.15.
8
Surgery on primary tumor shows survival benefit in selected stage IV colon cancer patients: A real-world study based on SEER database.对原发性肿瘤进行手术对特定的IV期结肠癌患者显示出生存获益:一项基于监测、流行病学和最终结果(SEER)数据库的真实世界研究。
J Cancer. 2020 Mar 15;11(12):3567-3579. doi: 10.7150/jca.43518. eCollection 2020.
9
Does primary tumor resection contribute to overall survival in unresectable synchronous metastatic colorectal cancer?原发性肿瘤切除对不可切除的同步转移性结直肠癌的总生存期有贡献吗?
J Res Med Sci. 2020 Feb 20;25:14. doi: 10.4103/jrms.JRMS_1056_18. eCollection 2020.
10
Surgical approach to synchronous colorectal liver metastases: staged, combined, or reverse strategy.同步性结直肠癌肝转移的手术治疗方法:分期、联合或逆向策略。
Hepatobiliary Surg Nutr. 2020 Feb;9(1):25-34. doi: 10.21037/hbsn.2019.05.14.

本文引用的文献

1
Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma.丝裂霉素-C持续静脉输注联合5-氟尿嘧啶昼夜定时输注治疗晚期结直肠癌的III期研究
Clin Colorectal Cancer. 2004 Feb;3(4):235-42. doi: 10.3816/CCC.2004.n.004.
2
Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer.转移性直肠癌患者在未行结肠造口术的情况下,采用初始放化疗有效控制盆腔症状。
Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):107-16. doi: 10.1016/s0360-3016(00)00777-x.
3
Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group.晚期结直肠癌的姑息化疗:系统评价与荟萃分析。结直肠癌协作组
BMJ. 2000 Sep 2;321(7260):531-5. doi: 10.1136/bmj.321.7260.531.
4
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.亚叶酸钙与氟尿嘧啶联合或不联合奥沙利铂作为晚期结直肠癌的一线治疗方案。
J Clin Oncol. 2000 Aug;18(16):2938-47. doi: 10.1200/JCO.2000.18.16.2938.
5
Malignant colorectal obstruction treated by means of self-expanding metallic stents: effectiveness before surgery and in palliation.自膨式金属支架治疗恶性大肠梗阻:术前及姑息治疗的有效性
Radiology. 2000 Aug;216(2):492-7. doi: 10.1148/radiology.216.2.r00au12492.
6
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.伊立替康联合氟尿嘧啶与单纯氟尿嘧啶作为转移性结直肠癌一线治疗的比较:一项多中心随机试验。
Lancet. 2000 Mar 25;355(9209):1041-7. doi: 10.1016/s0140-6736(00)02034-1.
7
Nonoperative management of primary colorectal cancer in patients with stage IV disease.IV期原发性结直肠癌患者的非手术治疗
Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7. doi: 10.1007/s10434-999-0651-x.
8
Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.预测转移性结直肠癌肝切除术后复发的临床评分:1001例连续病例分析
Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21. doi: 10.1097/00000658-199909000-00004.
9
Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases.2230例韩国结直肠癌患者的预后因素:对连续手术病例的分析
World J Surg. 1999 Jul;23(7):721-6. doi: 10.1007/pl00012376.
10
Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma.转移部位作为晚期结直肠癌反应和预后的额外预测指标的影响
Br J Cancer. 1999 Apr;79(11-12):1800-5. doi: 10.1038/sj.bjc.6690287.

不可切除的原发性结直肠癌和同步转移患者化疗后的肠道并发症。

Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases.

作者信息

Tebbutt N C, Norman A R, Cunningham D, Hill M E, Tait D, Oates J, Livingston S, Andreyev J

机构信息

Gastrointestinal Unit, Royal Marsden Hospital, London and Surrey, UK.

出版信息

Gut. 2003 Apr;52(4):568-73. doi: 10.1136/gut.52.4.568.

DOI:10.1136/gut.52.4.568
PMID:12631671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1773619/
Abstract

BACKGROUND

The role of palliative resection of the primary tumour in patients who present with metastatic colorectal cancer is unclear.

AIMS

This study compared the incidence of major intestinal complications in such patients who received chemotherapy treatment with or without prior palliative resection of the primary tumour.

PATIENTS

The incidence of intestinal obstruction, perforation, fistula formation, and gastrointestinal haemorrhage, and the requirement for abdominal radiotherapy in patients with metastatic colorectal cancer treated at a single institution over a 10 year period was determined.

RESULTS

Eighty two patients received initial treatment with chemotherapy without resection of the primary tumour (unresected group) and 280 patients had undergone prior resection (resected group). In the unresected group, the incidence of peritonitis, fistula formation, and intestinal haemorrhage was 2.4% (95% confidence interval (CI) 0.3-8.5%), 3.7% (95% CI 0.8-10.3%), and 3.7% (95% CI 0.8-10.3%), respectively, and was not significantly different from the resected group. Intestinal obstruction affected 13.4% (95% CI 6.9-22.7%) of patients in the unresected group and 13.2% (95% CI 9.2-17.2%) of patients in the resected group. More patients in the unresected group required >/=3 blood transfusions (14.6% v 7.5%; p=0.048) and abdominal radiotherapy (18.3% v 9.6%; p=0.03) than the resected group.

CONCLUSIONS

The incidence of major intestinal complications in patients with unresected colorectal cancer and synchronous metastases who receive initial treatment with chemotherapy is low. Chemotherapy may be successfully used as initial treatment for such patients with no increased risk of most major intestinal complications compared with patients who have undergone initial resection of the primary tumour.

摘要

背景

对于出现转移性结直肠癌的患者,原发肿瘤姑息性切除的作用尚不清楚。

目的

本研究比较了接受化疗治疗的此类患者在有无原发肿瘤姑息性切除的情况下,严重肠道并发症的发生率。

患者

确定了在一家机构接受治疗的转移性结直肠癌患者在10年期间肠梗阻、穿孔、瘘管形成和胃肠道出血的发生率,以及腹部放疗的需求。

结果

82例患者接受了初始化疗且未切除原发肿瘤(未切除组),280例患者曾接受过切除(切除组)。在未切除组中,腹膜炎、瘘管形成和肠道出血的发生率分别为2.4%(95%置信区间(CI)0.3 - 8.5%)、3.7%(95%CI 0.8 - 10.3%)和3.7%(95%CI 0.8 - 10.3%),与切除组无显著差异。肠梗阻影响未切除组13.4%(95%CI 6.9 - 22.7%)的患者和切除组13.2%(95%CI 9.2 - 17.2%)的患者。未切除组中需要≥3次输血(14.6%对7.5%;p = 0.048)和腹部放疗(18.3%对9.6%;p = 0.03)的患者比切除组更多。

结论

未切除的结直肠癌并伴有同步转移且接受初始化疗治疗的患者,严重肠道并发症的发生率较低。与接受过原发肿瘤初始切除的患者相比,化疗可成功用作此类患者的初始治疗,且大多数严重肠道并发症的风险不会增加。